Why Illumina Stock Is Sinking Today

What happened

Shares of Illumina (NASDAQ: ILMN) are sinking today, down 6.7% as of 11:48 a.m. EDT, after the genomic-sequencing specialist announced that it plans to acquire GRAIL for $8 billion.

So what

Illumina actually founded GRAIL in 2016 but later spun out the company as a stand-alone entity. GRAIL is focused on the development of liquid biopsies: blood tests that detect cancer by identifying fragments of DNA separated from tumor cells.

DNA double helix hovering over an outstretched palm

Image source: Getty Images.

GRAIL is targeting a total addressable market that could grow to $75 billion by 2035. So why were investors not happy with Illumina's acquisition news? Probably because of the price tag of the deal.

Earlier this month, GRAIL filed for an initial public offering (IPO). Its valuation as it prepared to go public was estimated to be around $1.9 billion. Illumina will spend four times that amount to get a company that doesn't have any products on the market yet and that has no steady source of revenue. The fact that Illumina is investing so much to get a company that it already owned just a few years ago makes the deal even harder to swallow for investors.

Now what

The price that Illumina is paying for GRAIL won't matter over the long run -- if GRAIL is successful in developing and marketing liquid biopsy products. GRAIL hopes to launch its first product, multicancer early detection test Galleri, next year for laboratory use only. With Illumina's shares trading at more than 42 times expected earnings, the company will need to deliver some good news soon to convince investors the healthcare stock is worth buying at its premium valuation.

10 stocks we like better than Illumina
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Illumina wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of August 1, 2020


Keith Speights owns shares of Illumina. The Motley Fool owns shares of and recommends Illumina. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.